Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.30 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20513711 | 0.97 | MAPT (0.33) | MAPTLMNAGPBAR1CYSLTR1TRPA1 | |
| SCHEMBL20513826 | 0.84 | LMNA (0.34) | MAPTLMNAGPBAR1CYSLTR1TRPA1 | |
| SCHEMBL5032369 | 0.78 | LMNA (0.37) | MAPTLMNAGPBAR1CYSLTR1TRPA1 | |
| SCHEMBL5031092 | 0.78 | LMNA (0.37) | MAPTLMNAGPBAR1CYSLTR1TRPA1 | |
| SCHEMBL20513571 | 0.72 | LTA4H (0.35) | LMNAL3MBTL1LTA4H | |
| SCHEMBL20513246 | 0.72 | KDM4E (0.36) | LMNAMTNR1AMTNR1BMAOAPTGS1 | |
| SCHEMBL11394822 | 0.71 | MAPT (0.38) | MAPTLMNAGPBAR1CYSLTR1ALDH1A1 | |
| SCHEMBL20514125 | 0.71 | — | — | |
| SCHEMBL20513889 | 0.71 | — | — | |
| SCHEMBL20513247 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795064-B2 | Polymetalloxane, method for producing same, composition thereof, cured film and method for producing same, and members and electronic components provided with same | TORAY INDUSTRIES, INC. (JP) | 2023-10-24 | — | — | US | disclosed |
| EP-3381969-B1 | POLYMETALLOXANE, METHOD FOR PRODUCING SAME, COMPOSITION THEREOF, CURED FILM AND METHOD FOR PRODUCING SAME, AND MEMBERS AND ELECTRONIC COMPONENTS PROVIDED WITH SAME | TORAY INDUSTRIES (JP) | 2020-06-03 | — | — | EP | disclosed |
| US-20180327275-A1 | POLYMETALLOXANE, METHOD FOR PRODUCING SAME, COMPOSITION THEREOF, CURED FILM AND METHOD FOR PRODUCING SAME, AND MEMBERS AND ELECTRONIC COMPONENTS PROVIDED WITH SAME | TORAY INDUSTRIES, INC. (JP) | 2018-11-15 | — | — | US | disclosed |
| EP-3381969-A1 | POLYMETALLOXANE, METHOD FOR PRODUCING SAME, COMPOSITION THEREOF, CURED FILM AND METHOD FOR PRODUCING SAME, AND MEMBERS AND ELECTRONIC COMPONENTS PROVIDED WITH SAME | Toray Industries, Inc. (JP) | 2018-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795064-B2 | Polymetalloxane, method for producing same, composition thereof, cured film and method for producing same, and members and electronic components provided with same | ASH2L, SETDB1, BMI1 | MAPT 1602/4885LMNA 2451/4885GPBAR1 4262/4885 |
| US-20180327275-A1 | POLYMETALLOXANE, METHOD FOR PRODUCING SAME, COMPOSITION THEREOF, CURED FILM AND METHOD FOR PRODUCING SAME, AND MEMBERS AND ELECTRONIC COMPONENTS PROVIDED WITH SAME | ASH2L, SETDB1, BMI1 | MAPT 1602/4885LMNA 2451/4885GPBAR1 4262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.